Duloxetine Protects Retina in Retinitis Pigmentosa Model

Researchers from the University of Alicante and the Teófilo Hernando Foundation propose the drug for various degenerative eye diseases.

Generic image of a laboratory with scientific equipment and a blue liquid in a dish.
AI

Generic image of a laboratory with scientific equipment and a blue liquid in a dish.

Scientists from the Pharmacology area at the University of Alicante (UA) and the Teófilo Hernando Foundation have demonstrated that duloxetine, a drug used for depression and neuropathic pain, protects the retina in a mouse model of retinitis pigmentosa.

The research, conducted by the Pharmacology and Physiology of Neurodegenerative Diseases (FarmaFisEn) group at the UA, led by Professor Victoria Maneu, has found in mice that duloxetine improves both retinal structure and function, and reduces inflammatory markers. These findings suggest the drug could potentially be used for other degenerative retinal diseases, such as central areolar choroidal dystrophy, glaucoma, diabetic retinopathy, macular degeneration, and retinopathy associated with Alzheimer's and Parkinson's diseases.
This study exemplifies drug repositioning, a strategy seeking new therapeutic applications for already approved medications. As its safety and behavior in the body are known, human trials may bypass some initial research phases, reducing costs and timelines compared to developing a drug from scratch.
Duloxetine could be administered through various routes, including oral, intravenous, direct topical application to the eye, or via an ocular implant. However, the work is still in a basic research phase and has only been tested in this mouse model.
Retinal degenerative diseases cause severe vision problems and, often, blindness, with significant social, health, and economic impact. Despite different causes (genetic defects, intraocular pressure, high blood glucose, stress, aging), many cellular and molecular injury response mechanisms are similar across these conditions, frequently inducing controlled cell death and retinal remodeling.
Current treatments have limited effectiveness in modifying the progression of these diseases, highlighting the need for more efficient drugs capable of delaying photoreceptor degeneration and subsequent vision loss.
To facilitate the development and commercial exploitation of this technology, the Service for the Transfer of Research Results (OTRI) at the UA has launched a technology offer. They are seeking pharmaceutical companies specializing in ophthalmology and neurobiology interested in acquiring the patent through licensing agreements, R&D projects, or proof-of-concept studies.
Based on information from the official source: Universidad de Alicante (19/11/2026)